Advertisement
Advertisement
Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 59.66 |
| Open | 59.84 |
| Bid | 42.42 x 1400 |
| Ask | 99.93 x 800 |
| Day's Range | 58.65 - 63.28 |
| 52 Week Range | 45.20 - 104.38 |
| Volume | |
| Avg. Volume | 565,835 |
| Market Cap | 4.349B |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 51% loss from investing in the stock a year ago
Taking the occasional loss comes part and parcel with investing on the stock market. And there's no doubt that...
- Zacks
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
- Zacks
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
